Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Colorectal Cancer Screening-Who, How, and When?

  • Bevan, Roisin (Department of Gastroenterology, University Hospital of North Tees) ;
  • Rutter, Matthew D (Department of Gastroenterology, University Hospital of North Tees)
  • Received : 2017.09.05
  • Accepted : 2017.10.20
  • Published : 2018.01.30
⟨ Previous Next ⟩

Abstract

Colorectal cancer (CRC) is the third most common cancer worldwide. It is amenable to screening as it occurs in premalignant, latent, early, and curable stages. PubMed, Cochrane Database of Systematic Reviews, and national and international CRC screening guidelines were searched for CRC screening methods, populations, and timing. CRC screening can use direct or indirect tests, delivered opportunistically or via organized programs. Most CRCs are diagnosed after 60 years of age; most screening programs apply to individuals 50-75 years of age. Screening may reduce disease-specific mortality by detecting CRC in earlier stages, and CRC incidence by detecting premalignant polyps, which can subsequently be removed. In randomized controlled trials (RCTs) guaiac fecal occult blood testing (gFOBt) was found to reduce CRC mortality by 13%-33%. Fecal immunochemical testing (FIT) has no RCT data comparing it to no screening, but is superior to gFOBt. Flexible sigmoidoscopy (FS) trials demonstrated an 18% reduction in CRC incidence and a 28% reduction in CRC mortality. Currently, RCT evidence for colonoscopy screening is scarce. Although not yet corroborated by RCTs, it is likely that colonoscopy is the best screening modality for an individual. From a population perspective, organized programs are superior to opportunistic screening. However, no nation can offer organized population-wide colonoscopy screening. Thus, organized programs using cheaper modalities, such as FS/FIT, can be tailored to budget and capacity.

Keywords

References

  1. International Agency for Research on Cancer. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012 [Internet]. Lyon: IARC; c2012 [cited 2017 Sep 5]. Available from: http://globocan.iarc.fr/Default.aspx.
  2. Center MM, Jemal A, Smith RA, Ward E. Worldwide variations in colorectal cancer. CA Cancer J Clin 2009;59:366-378. https://doi.org/10.3322/caac.20038
  3. Burt RW, Barthel JS, Dunn KB, et al. NCCN clinical practice guidelines in oncology. Colorectal cancer screening. J Natl Compr Canc Netw 2010;8:8-61. https://doi.org/10.6004/jnccn.2010.0003
  4. Cancer Research UK. Bowel cancer statistics [Internet]. London: Cancer Research UK; c2015 [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer?_ga=2.199557997.216204478. 1517035023-396171367.1516104333#heading-Zero.
  5. Cancer Research UK. Bowel cancer incidence statistics [Internet]. London: Cancer Research UK; c2015 [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer/incidence?_ga=2.130656591.172763994.1517148794-396171367.1516104333#heading-Eleven.
  6. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009;18:1688-1694. https://doi.org/10.1158/1055-9965.EPI-09-0090
  7. Valori R, Rutter M, Aravani A, Rashbass J, Vernon S, Morris EJA. National early diagnosis initiatives and their impact on the incidence of colorectal cancer in England. United European Gastroenterol J 2016;4:800-811. https://doi.org/10.1177/2050640616678364
  8. Welch HG, Robertson DJ. Colorectal cancer on the decline--why screening can't explain it all. N Engl J Med 2016;374:1605-1607. https://doi.org/10.1056/NEJMp1600448
  9. Gavin DR, Valori RM, Anderson JT, Donnelly MT, Williams JG, Swarbrick ET. The national colonoscopy audit: a nationwide assessment of the quality and safety of colonoscopy in the UK. Gut 2013;62:242-249. https://doi.org/10.1136/gutjnl-2011-301848
  10. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968;65:281-393.
  11. Leslie A, Carey FA, Pratt NR, Steele RJ. The colorectal adenoma-carcinoma sequence. Br J Surg 2002;89:845-860. https://doi.org/10.1046/j.1365-2168.2002.02120.x
  12. Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer 1992;70(6 Suppl):1727-1731. https://doi.org/10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P
  13. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol 2011;42:1-10. https://doi.org/10.1016/j.humpath.2010.06.002
  14. Cancer Research UK. Cancer incidence for all cancers combined [Internet]. London: Cancer Research UK; c2015 [cited 2017 Sep 5]. Available from: http://www.cancerresearchuk.org/health-professional/cancer-statistics/incidence/all-cancers-combined?_ga=2.34114657.172763994.1517148794-396171367.1516104333.
  15. Rees CJ, Bevan R. The national health service bowel cancer screening program: the early years. Expert Rev Gastroenterol Hepatol 2013;7:421-437. https://doi.org/10.1586/17474124.2013.811045
  16. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM. American college of gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol 2009;104:739-750. https://doi.org/10.1038/ajg.2009.104
  17. Schreuders EH, Ruco A, Rabeneck L, et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015;64:1637-1649. https://doi.org/10.1136/gutjnl-2014-309086
  18. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut 2010;59:666-689. https://doi.org/10.1136/gut.2009.179804
  19. Rex DK, Bond JH, Winawer S, et al. Quality in the technical performance of colonoscopy and the continuous quality improvement process for colonoscopy: recommendations of the U.S. multi-society task force on colorectal cancer. Am J Gastroenterol 2002;97:1296-1308. https://doi.org/10.1111/j.1572-0241.2002.05812.x
  20. U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. preventive services task force recommendation statement. Ann Intern Med 2008;149:627-637. https://doi.org/10.7326/0003-4819-149-9-200811040-00243
  21. Fletcher RH. Diet for fecal occult blood test screening: help or harm? Eff Clin Pract 2001;4:180-182.
  22. Rabeneck L, Rumble RB, Thompson F, et al. Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol 2012;26:131-147. https://doi.org/10.1155/2012/486328
  23. Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;(1):CD001216.
  24. Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996;348:1472-1477. https://doi.org/10.1016/S0140-6736(96)03386-7
  25. Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996;348:1467-1471. https://doi.org/10.1016/S0140-6736(96)03430-7
  26. Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 1999;91:434-437. https://doi.org/10.1093/jnci/91.5.434
  27. Kewenter J, Brevinge H, Engaras B, Haglind E, Ahren C. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-473. https://doi.org/10.3109/00365529409096840
  28. Logan RF, Patnick J, Nickerson C, Coleman L, Rutter MD, von Wagner C. Outcomes of the bowel cancer screening programme (BCSP) in England after the first 1 million tests. Gut 2012;61:1439-1446. https://doi.org/10.1136/gutjnl-2011-300843
  29. Leuraud K, Jezewski-Serra D, Viguier J, Salines E. Colorectal cancer screening by guaiac faecal occult blood test in France: Evaluation of the programme two years after launching. Cancer Epidemiol 2013;37:959-967. https://doi.org/10.1016/j.canep.2013.07.008
  30. Pitkaniem J, Seppa K, Hakama M, et al. Effectiveness of screening for colorectal cancer with a faecal occult-blood test, in Finland. BMJ Open Gastroenterol 2015;2:e000034. https://doi.org/10.1136/bmjgast-2015-000034
  31. Paimela H, Malila N, Palva T, Hakulinen T, Vertio H, Jarvinen H. Early detection of colorectal cancer with faecal occult blood test screening. Br J Surg 2010;97:1567-1571. https://doi.org/10.1002/bjs.7150
  32. Steele RJ, McClements PL, Libby G, et al. Results from the first three rounds of the Scottish demonstration pilot of FOBT screening for colorectal cancer. Gut 2009;58:530-535. https://doi.org/10.1136/gut.2008.162883
  33. Malila N, Anttila A, Hakama M. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004. J Med Screen 2005;12:28-32. https://doi.org/10.1258/0969141053279095
  34. Katicic M, Antoljak N, Kujundzic M, et al. Results of national colorectal cancer screening program in Croatia (2007-2011). World J Gastroenterol 2012;18:4300-4307. https://doi.org/10.3748/wjg.v18.i32.4300
  35. Geraghty J, Butler P, Seaman H, et al. Optimising faecal occult blood screening:retrospective analysis of NHS bowel cancer screening data to improve the screening algorithm. Br J Cancer 2014;111:2156-2162. https://doi.org/10.1038/bjc.2014.480
  36. Holme O, Bretthauer M, Fretheim A, Odgaard-Jensen J, Hoff G. Flexible sigmoidoscopy versus faecal occult blood testing for colorectal cancer screening in asymptomatic individuals. Cochrane Database Syst Rev 2013;(9):CD009259.
  37. Bretthauer M. Colorectal cancer screening. J Intern Med 2011;270:87-98. https://doi.org/10.1111/j.1365-2796.2011.02399.x
  38. von Wagner C, Baio G, Raine R, et al. Inequalities in participation in an organized national colorectal cancer screening programme: results from the first 2.6 million invitations in England. Int J Epidemiol 2011;40:712-718. https://doi.org/10.1093/ije/dyr008
  39. Palmer CK, Thomas MC, von Wagner C, Raine R. Reasons for non-uptake and subsequent participation in the NHS bowel cancer screening programme: a qualitative study. Br J Cancer 2014;110:1705-1711. https://doi.org/10.1038/bjc.2014.125
  40. Bradley DT, Treanor C, McMullan C, Owen T, Graham A, Anderson D. Reasons for non-participation in the Northern Ireland bowel cancer screening programme: a qualitative study. BMJ Open 2015;5:e008266. https://doi.org/10.1136/bmjopen-2015-008266
  41. Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin 2003;53:44-55. https://doi.org/10.3322/canjclin.53.1.44
  42. Steele RJ, McDonald PJ, Digby J, et al. Clinical outcomes using a faecal immunochemical test for haemoglobin as a first-line test in a national programme constrained by colonoscopy capacity. United European Gastroenterol J 2013;1:198-205. https://doi.org/10.1177/2050640613489281
  43. Lee JK, Liles EG, Bent S, Levin TR, Corley DA. Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta- analysis. Ann Intern Med 2014;160:171.
  44. Kapidzic A, van Roon AH, van Leerdam ME, et al. Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. Gut 2017;66:118-123. https://doi.org/10.1136/gutjnl-2014-308957
  45. Hol L, Wilschut JA, van Ballegooijen M, et al. Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels. Br J Cancer 2009;100:1103-1110. https://doi.org/10.1038/sj.bjc.6604961
  46. Haug U, Grobbee EJ, Lansdorp-Vogelaar I, Spaander MCW, Kuipers EJ. Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended? Gut 2017;66:1262-1267. https://doi.org/10.1136/gutjnl-2015-310102
  47. Allison JE, Fraser CG, Halloran SP, Young GP. Comparing fecal immunochemical tests: improved standardization is needed. Gastroenterology 2012;142:422-424. https://doi.org/10.1053/j.gastro.2012.01.015
  48. van Rossum LG, van Rijn AF, Laheij RJ, et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008;135:82-90. https://doi.org/10.1053/j.gastro.2008.03.040
  49. Hol L, van Leerdam ME, van Ballegooijen M, et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010;59:62-68. https://doi.org/10.1136/gut.2009.177089
  50. Holme O, Loberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312:606-615. https://doi.org/10.1001/jama.2014.8266
  51. Schreuders EH, Grobbee EJ, Spaander MC, Kuipers EJ. Advances in fecal tests for colorectal cancer screening. Curr Treat Options Gastroenterol 2016;14:152-162. https://doi.org/10.1007/s11938-016-0076-0
  52. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010;375:1624-1633. https://doi.org/10.1016/S0140-6736(10)60551-X
  53. Hoff G, Grotmol T, Skovlund E, Bretthauer M; Norwegian Colorectal Cancer Prevention Study Group. Risk of colorectal cancer seven years after flexible sigmoidoscopy screening: randomised controlled trial. BMJ 2009;338:b1846. https://doi.org/10.1136/bmj.b1846
  54. Segnan N, Armaroli P, Bonelli L, et al. Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian randomized controlled trial--SCORE. J Natl Cancer Inst 2011;103:1310-1322. https://doi.org/10.1093/jnci/djr284
  55. Schoen RE, Pinsky PF, Weissfeld JL, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-2357. https://doi.org/10.1056/NEJMoa1114635
  56. Atkin WS, Cook CF, Cuzick J, Edwards R, Northover JM, Wardle J. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002;359:1291-1300. https://doi.org/10.1016/S0140-6736(02)08268-5
  57. Gondal G, Grotmol T, Hofstad B, Bretthauer M, Eide TJ, Hoff G. The Norwegian colorectal cancer prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50-64 years. Scand J Gastroenterol 2003;38:635-642. https://doi.org/10.1080/00365520310003002
  58. Brenner H, Stock C, Hoffmeister M. Effect of screening sigmoidoscopy and screening colonoscopy on colorectal cancer incidence and mortality: systematic review and meta-analysis of randomised controlled trials and observational studies. BMJ 2014;348:g2467. https://doi.org/10.1136/bmj.g2467
  59. Holme O, Schoen RE, Senore C, et al. Effectiveness of flexible sigmoidoscopy screening in men and women and different age groups: pooled analysis of randomised trials. BMJ 2017;356:i6673.
  60. Atkin W, Wooldrage K, Parkin DM, et al. Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up: the UK flexible sigmoidoscopy screening randomised controlled trial. Lancet 2017;389:1299-1311. https://doi.org/10.1016/S0140-6736(17)30396-3
  61. Bevan R, Rubin G, Sofianopoulou E, Patnick J, Rees CJ. Implementing a national flexible sigmoidoscopy screening program: results of the English early pilot. Endoscopy 2015;47:225-231. https://doi.org/10.1055/s-0034-1365383
  62. Neilson LJ, Bevan R, Nickerson C, et al. Bowelscope- results from the pilot sites. Gut;64(Suppl 1):A370.
  63. Tang V, Boscardin WJ, Stijacic-Cenzer I, Lee SJ. Time to benefit for colorectal cancer screening: survival meta-analysis of flexible sigmoidoscopy trials. BMJ 2015;350:h1662. https://doi.org/10.1136/bmj.h1662
  64. Segnan N, Senore C, Andreoni B, et al. Baseline findings of the Italian multicenter randomized controlled trial of “once-only sigmoidoscopy”-- SCORE. J Natl Cancer Inst 2002;94:1763-1772. https://doi.org/10.1093/jnci/94.23.1763
  65. Masseria C. Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment. Eur J Health Econ 2010;10 Suppl 1:S41-S49. https://doi.org/10.1007/s10198-009-0191-0
  66. Moss S, Mathews C, Day TJ, et al. Increased uptake and improved outcomes of bowel cancer screening with a faecal immunochemical test: results from a pilot study within the national screening programme in England. Gut 2017;66:1631-1644. https://doi.org/10.1136/gutjnl-2015-310691
  67. von Wagner C, Bowyer H, Rees CJ, Atkin W, Wardle J. Patient-reported experience of comfort and dignity in flexible sigmoidoscopy: data from the NHS bowel scope screening pilot. Gut 2014;63(Suppl 1):A137.
  68. Morris EJ, Rutter MD, Finan PJ, Thomas JD, Valori R. Post-colonoscopy colorectal cancer (PCCRC) rates vary considerably depending on the method used to calculate them: a retrospective observational population-based study of PCCRC in the English national health service. Gut 2015;64:1248-1256. https://doi.org/10.1136/gutjnl-2014-308362
  69. Corley DA, Jensen CD, Marks AR, et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014;370:1298-1306. https://doi.org/10.1056/NEJMoa1309086
  70. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010;362:1795-1803. https://doi.org/10.1056/NEJMoa0907667
  71. Bowles CJ, Leicester R, Romaya C, Swarbrick E, Williams CB, Epstein O. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow? Gut 2004;53:277-283. https://doi.org/10.1136/gut.2003.016436
  72. Lee TJ, Rutter MD, Blanks RG, et al. Colonoscopy quality measures: experience from the NHS bowel cancer screening programme. Gut 2012;61:1050-1057. https://doi.org/10.1136/gutjnl-2011-300651
  73. Regula J, Zagorowicz E, Butruk E. Implementation of a national colorectal cancer screening program. Curr Colorectal Cancer Rep 2006;2:25-29. https://doi.org/10.1007/s11888-006-0014-y
  74. Kaminski MF, Kraszewska E, Rupinski M, Laskowska M, Wieszczy P, Regula J. Design of the polish colonoscopy screening program: a randomized health services study. Endoscopy 2015;47:1144-1150. https://doi.org/10.1055/s-0034-1392769
  75. Quintero E, Castells A, Bujanda L, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706. https://doi.org/10.1056/NEJMoa1108895
  76. Kaminski MF, Bretthauer M, Zauber AG, et al. The NordICC study: rationale and design of a randomized trial on colonoscopy screening for colorectal cancer. Endoscopy 2012;44:695-702. https://doi.org/10.1055/s-0032-1306895
  77. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-1981. https://doi.org/10.1056/NEJM199312303292701
  78. Citarda F, Tomaselli G, Capocaccia R, Barcherini S, Crespi M. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001;48:812-815. https://doi.org/10.1136/gut.48.6.812
  79. Tappenden P, Chilcott J, Eggington S, Patnick J, Sakai H, Karnon J. Option appraisal of population-based colorectal cancer screening programmes in England. Gut 2007;56:677-684. https://doi.org/10.1136/gut.2006.095109
  80. Rutter MD, Nickerson C, Rees CJ, Patnick J, Blanks RG. Risk factors for adverse events related to polypectomy in the English bowel cancer screening programme. Endoscopy 2014;46:90-97. https://doi.org/10.1055/s-0033-1344987
  81. Bevan R, Nickerson C, Patnick J, et al. Bowelscope: early results from the pilot sites. Gut 2014;63(Suppl 1):A145.
  82. Ghanouni A, Plumb A, Rees CJ, et al. Patients' experience of colonoscopy in the English bowel cancer screening programme. Gut 2014;63(Suppl 1):A137-A138.
  83. Plumb AA, Ghanouni A, Rees CJ, et al. Comparison of patient experience of colonoscopy and CT colonography in the English bowel cancer screening programme. Gut 2014;63(Suppl 1):A136-A137.
  84. Spada C, Hassan C, Galmiche JP, et al. Colon capsule endoscopy: European society of gastrointestinal endoscopy (ESGE) guideline. Endoscopy 2012;44:527-536. https://doi.org/10.1055/s-0031-1291717
  85. Spada C, Hassan C, Marmo R, et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol 2010;8:516-522. https://doi.org/10.1016/j.cgh.2010.02.018
  86. Rokkas T, Papaxoinis K, Triantafyllou K, Ladas SD. A meta-analysis evaluating the accuracy of colon capsule endoscopy in detecting colon polyps. Gastrointest Endosc 2010;71:792-798. https://doi.org/10.1016/j.gie.2009.10.050
  87. Sacher-Huvelin S, Coron E, Gaudric M, et al. Colon capsule endoscopy vs. colonoscopy in patients at average or increased risk of colorectal cancer. Aliment Pharmacol Ther 2010;32:1145-1153. https://doi.org/10.1111/j.1365-2036.2010.04458.x
  88. Triantafyllou K, Viazis N, Tsibouris P, et al. Colon capsule endoscopy is feasible to perform after incomplete colonoscopy and guides further workup in clinical practice. Gastrointest Endosc 2014;79:307-316. https://doi.org/10.1016/j.gie.2013.07.061
  89. Groth S, Krause H, Behrendt R, et al. Capsule colonoscopy increases uptake of colorectal cancer screening. BMC Gastroenterol 2012;12:80. https://doi.org/10.1186/1471-230X-12-80
  90. Alberti LR, Garcia DP, Coelho DL, De Lima DC, Petroianu A. How to improve colon cancer screening rates. World J Gastrointest Oncol 2015;7:484-491. https://doi.org/10.4251/wjgo.v7.i12.484
  91. Halligan S, Wooldrage K, Dadswell E, et al. Computed tomographic colonography versus barium enema for diagnosis of colorectal cancer or large polyps in symptomatic patients (SIGGAR): a multicentre randomised trial. Lancet 2013;381:1185-1193. https://doi.org/10.1016/S0140-6736(12)62124-2
  92. von Wagner C, Smith S, Halligan S, et al. Patient acceptability of CT colonography compared with double contrast barium enema: results from a multicentre randomised controlled trial of symptomatic patients. Eur Radiol 2011;21:2046-2055. https://doi.org/10.1007/s00330-011-2154-y
  93. von Wagner C, Ghanouni A, Halligan S, et al. Patient acceptability and psychologic consequences of CT colonography compared with those of colonoscopy: results from a multicenter randomized controlled trial of symptomatic patients. Radiology 2012;263:723-731. https://doi.org/10.1148/radiol.12111523
  94. Lin OS, Kozarek RA, Gluck M, et al. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies. J Gen Intern Med 2012;27:1349-1360. https://doi.org/10.1007/s11606-012-2115-4
  95. Tappenden P, Eggington S, Richard Nixon R, Chilcott J, Sakai H, Karnon J. Colorectal cancer screening options appraisal: cost-effectiveness, cost-utility and resource impact of alternative screening options for colorectal cancer [Internet]. Sheffield: The University of Sheffield; c2004 [updated 2004 Sep; cited 2017 Sep 5]. Available from: https://pdfs.semanticscholar.org/09a0/8003b99c2abaf7d49308229a72ddfe54f677.pdf.
  96. Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening-age to begin, age to stop, and timing of screening intervals. Rockville (MD): Agency for Healthcare Research and Quality (US);2009.
  97. Zauber AG, Knudsen AB, Carolyn R, et al. Evaluating the benefits and harms of colorectal cancer screening strategies: a collaborative modeling approach to inform the US preventive services task force. Gastroenterology 2016;150(4 Suppl 1):S46.
  98. U.S. Preventive Services Task Force. Draft evidence review for colorectal cancer: screening [Internet]. Rockville (MD): U.S. Preventive Services Task Force; c2015 [updated 2015 Oct; cited 2017 Sep 5]. Available from: https://www.uspreventiveservicestaskforce.org/Page/Document/draft-evidence-review54/colorectal-cancer-screening2.
  99. Harewood GC, Lawlor GO, Larson MV. Incident rates of colonic neoplasia in older patients: when should we stop screening? J Gastroenterol Hepatol 2006;21:1021-1025. https://doi.org/10.1111/j.1440-1746.2006.04218.x
  100. Brenner H. Colorectal cancer screening for older adults. BMJ 2015;350:h2029. https://doi.org/10.1136/bmj.h2029
  101. Qaseem A, Denberg TD, Hopkins RH Jr, et al. Screening for colorectal cancer: a guidance statement from the American college of physicians. Ann Intern Med 2012;156:378-386. https://doi.org/10.7326/0003-4819-156-5-201203060-00010
  102. Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the US multi-society task force on colorectal cancer and the American cancer society. Gastroenterology 2006;130:1872-1885. https://doi.org/10.1053/j.gastro.2006.03.012

Cited by

  1. Microbial markers in colorectal cancer detection and/or prognosis vol.24, pp.22, 2018, https://doi.org/10.3748/wjg.v24.i22.2327
  2. A Soft Pneumatic Inchworm Double balloon (SPID) for colonoscopy vol.9, pp.None, 2019, https://doi.org/10.1038/s41598-019-47320-3
  3. Is it Possible to Successfully Treat Locally Advanced Colon Cancer Using Pre-Operative Chemoradiotherapy? vol.52, pp.2, 2018, https://doi.org/10.5946/ce.2018.088
  4. Colorectal Cancer Screening in People With and Without HIV in an Integrated Health Care Setting vol.81, pp.3, 2018, https://doi.org/10.1097/qai.0000000000002024
  5. Simulated performance of flexible sigmoidoscopy-based screening for advanced neoplasia detection in a Greek population vol.33, pp.2, 2018, https://doi.org/10.20524/aog.2020.0458
  6. Effects of Alternative Offers of Screening Sigmoidoscopy and Colonoscopy on Utilization and Yield of Endoscopic Screening for Colorectal Neoplasms: Protocol of the DARIO Randomized Trial vol.9, pp.8, 2018, https://doi.org/10.2196/17516
  7. Clinical outcomes of submucosal colorectal cancer diagnosed after endoscopic resection: a focus on the need for surgery vol.18, pp.1, 2018, https://doi.org/10.5217/ir.2019.00092
  8. DNA methylation and gene expression profiles characterize epigenetic regulation of lncRNAs in colon adenocarcinoma vol.121, pp.3, 2018, https://doi.org/10.1002/jcb.29463
  9. Colonoscopy using back brace support belt: A randomized, prospective trial vol.4, pp.3, 2018, https://doi.org/10.1002/jgh3.12276
  10. Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents vol.21, pp.5, 2020, https://doi.org/10.1208/s12249-020-01731-y
  11. Acceptance on colorectal cancer screening upper age limit in South Korea vol.26, pp.27, 2020, https://doi.org/10.3748/wjg.v26.i27.3959
  12. Association of low skeletal muscle mass with the presence of advanced colorectal neoplasm: integrative analysis using three skeletal muscle mass indices vol.22, pp.10, 2018, https://doi.org/10.1111/codi.15103
  13. Colonoscopy and flexible sigmoidoscopy for follow-up of patients with left-sided diverticulitis vol.102, pp.9, 2018, https://doi.org/10.1308/rcsann.2020.0181
  14. Race/ethnicity, sex and insurance disparities in colorectal cancer screening among individuals with and without cardiovascular disease vol.21, pp.None, 2020, https://doi.org/10.1016/j.pmedr.2020.101263
  15. Predictors of clinical outcomes of self-expandable metal stent treatment for malignant colorectal obstruction : A Honam Association for the Study of Intestinal Disease (HASID) multicenter study vol.100, pp.27, 2021, https://doi.org/10.1097/md.0000000000026616
  16. Gut Microbiota Profiles in Early- and Late-Onset Colorectal Cancer: A Potential Diagnostic Biomarker in the Future vol.102, pp.6, 2021, https://doi.org/10.1159/000516689
  17. A New Method for the Detection of Colorectal Cancer and the Precancerous Lesions: Occult Blood Testing Combination with Promoter Methylation in the Fecal Sample vol.12, pp.2, 2018, https://doi.org/10.7150/jca.50525
  18. Computed tomography colonography and radiation risk: How low can we go? vol.13, pp.3, 2018, https://doi.org/10.4253/wjge.v13.i3.72
  19. A Disintegrin and Metalloprotease 12 Promotes Tumor Progression by Inhibiting Apoptosis in Human Colorectal Cancer vol.13, pp.8, 2018, https://doi.org/10.3390/cancers13081927
  20. Current Landscape in Organic Nanosized Materials Advances for Improved Management of Colorectal Cancer Patients vol.14, pp.9, 2018, https://doi.org/10.3390/ma14092440
  21. Culturally-adapted behavioral intervention to improve colorectal cancer screening uptake among foreign-born South Asians in New Jersey: the Desi Sehat trial vol.26, pp.4, 2018, https://doi.org/10.1080/13557858.2018.1539219
  22. Comparable quality of bowel preparation with single‐day versus three‐day low‐residue diet: Randomized controlled trial vol.33, pp.5, 2018, https://doi.org/10.1111/den.13860
  23. Editors' Choice of Noteworthy Clinical Endoscopy Publications in the First Decade vol.54, pp.5, 2018, https://doi.org/10.5946/ce.2021.216
  24. Nanoparticle-Mediated Delivery Systems in Photodynamic Therapy of Colorectal Cancer vol.22, pp.22, 2018, https://doi.org/10.3390/ijms222212405
  25. Colorectal cancer in adolescents and young adults with Lynch syndrome: a Danish register-based study vol.11, pp.12, 2018, https://doi.org/10.1136/bmjopen-2021-053538